Benefits |
| |
Benefits to labs |
|
Operational Benefits |
|
Addresses key sources of error and cost, such as observer fatigue and visual habituation, variability in screening techniques, high complexity of cell morphology and rarity of abnormal cells. |
|
Provides laboratory with complete control of work flow and quality, as entire system is located on-site with remote interface capabilities. |
|
Automatically evaluates and ranks slides by likelihood of abnormality. |
|
Provides a complete turnkey system with built-in quality control checks for reliable and accurate results. |
|
Enables laboratory to concentrate on the 75% of slides most likely to contain abnormal cells while potentially archiving the remaining 25% as NILM. (optional capability).
|
|
Directed QC Technology™ exceeds U.S. Clinical Laboratory Improvement Amendment 1988 Quality Control requirement to Re-screen a minimum of 10% of slides initially classified as NILM. |
|
Helps focus cytotechnologist efforts on slides truly requiring human review.
|
|
May be operated by a laboratory assistant. Offers the convenience of unattended operation. |
|
Embodies the expertise of experienced Cytopathologists and Cytotechnologists. |
|
Automatically generates customizable work lists and slide sorting instructions; provides summaries of results, alerts (flagging inadequate samples), and archiving information. |
|
Potential to increase laboratory output and widen patient access to screening. |
|